Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
Biotech
CEO invests own cash to move NKGen toward Alzheimer’s readout
Song invested $2.65 million of his own money in NKGen to help accelerate the cash-strapped biotech’s phase 2 Alzheimer’s disease cell therapy trial.
Nick Paul Taylor
May 8, 2025 10:22am
Alzheon Alzheimer's drug knocked down in pivotal APOLLOE4 bout
Apr 10, 2025 8:48am
Roche gets patients below AD amyloid threshold after 28 weeks
Apr 3, 2025 9:30am
Cassava stops Alzheimer's program as simufilam fails again
Mar 25, 2025 9:12am
Oligomerix small molecule tamps down tau tangles in mice
Mar 14, 2025 12:30pm
Samsung backs Alzheimer's blood test developer C2N Diagnostics
Mar 13, 2025 12:15pm
